UK Parliament / Open data

Genetic Technology (Precision Breeding) Bill

My Lords, I note my interests as listed in the register, both as a farmer and as an IP and technology litigator at a law firm that represents clients active in this space.

I too welcome the noble Lord, Lord Roborough, to this House and congratulate him on an excellent maiden speech; I am glad to have another Devonian in our

midst, particularly one who is so close to the cream and who brings such a wealth of expertise in markets of natural capital.

While welcoming one new Member, I regret the retirement of another. Viscount Ridley would have contributed significantly to our review of this Bill, and his absence will be keenly felt. I hope his rebellious backing of my conservation covenant amendment last year did not contribute to his departure.

As a committed environmentalist, farmer and cross-border IP practitioner, for me, this is a significant and exciting Bill. It promises considerable benefits to our food supply, to animal welfare and to our national well-being; it can contribute to our net-zero ambitions, our climate resilience and our restoration of biodiversity; and it also provides great prospects for our innovative bioscience and agritech industries.

It is the last of these benefits that is probably the most exciting. Generally as a nation, we flatter ourselves in thinking that what we do on our very small island will move the needle much on global climate change, food supply or biodiversity; we simply do not have the land to make a significant difference. But with excellent universities and research centres, harnessing a structured and internationally accepted regulatory framework, we can make technological advances that have a significant impact on a global scale. That is the gold standard for which we must strive.

The Government are therefore to be congratulated on bringing forward this Bill, but they must also be wary that these bright and shiny opportunities do not blind us to the dangers that many fear from the technological developments being considered. For those comfortable with biotechnology and its regulation—and plenty of eminent speakers today fall into that category—these fears about gene editing and the use of precision breeding may seem misplaced, but they may indeed be fed by unreasonable suspicions and a certain amount of hyperbole and misinformation. I note that certain briefings mischievously describe gene editing as a form of “deregulated” or “exempt” genetic modification. However, we need to be mindful of public sentiment and bring consumers with us by openly developing robust safeguards, transparent regulatory processes and proper parliamentary oversight. The Government must temper their tendency to introduce critical policy through secondary legislation that sidesteps oversight and engenders mistrust.

There is a major public relations element to this Bill, and the Government must strive to educate in order to overcome the worrying statistics revealed by Defra’s public consultation. In our post-pandemic, social media-mired world, we cannot ignore the fact that the vast majority of individuals and businesses disagree with regulatory liberalisation for genetically edited organisms. Can the Minister please provide any insights into the public information efforts that will be introduced to support the aims of this Bill?

Public information leads us to the question of traceability and labelling. It is important that consumers are conscious of where their food comes from and how it was grown, and universal traceability of our diet is an important goal, particularly as we seek to

shorten supply chains and ensure producers are answerable for the manner in which our food is produced. But I do not think labelling is the answer here, as gene-edited produce that presents no additional risk to health or well-being should not be forced to compete unfairly with non-GE alternatives. If, as suggested, such produce actually improves health and animal welfare, or saves resources, then producers would undoubtedly extol those virtues in their own marketing.

I have already referenced the international export opportunities presented by this Bill, particularly for technology that can be developed. However, can we be certain that it presents no risks to our existing agricultural export business? Both the World Trade Organization and the European Commission are considering the regulation of gene-editing technology. Can the Minister please assure us that, by being an early adopter and taking a lone path, we will not unwittingly exclude ourselves from these international markets? In particular, what mechanisms are in place to ensure we maintain equivalence with future EU or WTO regulations?

I note some uncertainty regarding definitions and the market sectors impacted by this legislation. Briefings I have received focus largely on animals and plants for the food chain, but I trust the Bill will be equally applicable to silviculture and particularly the crucial development of disease-resistant and climate-resistant tree species, which are essential to the fulfilment of our extensive net-zero tree-planting commitments. Equally, I note that the legislation applies only to multicellular organisms. I wonder whether we are missing out by not addressing the opportunities presented by microbial proteins, which are single cell and an important alternative animal feed.

I agree with the concerns raised in the other place over animal welfare, and the fact that gene-editing technology must never be used to create animals able to withstand lower-standard living conditions. That said, it is a complex issue; for example, if we can help to create native breeds that survive in our inevitably hotter climate, that would surely be a good thing, even though some might say it enabled them to endure harsher living conditions.

The Bill asks much of the Food Standards Agency. I hope the FSA is prepared, and will be fit, for this important purpose.

I would be interested to understand the intellectual property implications of this legislation. Considerable intellectual property resides in the technologies developed to achieve gene editing, as seen in the extensive recent CRISPR technology disputes in the United States. Jurisdictions around the world remain uncertain and divided about the patentability of edited genes themselves, particularly where they are not otherwise naturally occurring. Can the Minister confirm whether the Government have considered that issue? It would be significant if gene-edited organisms were themselves protectable by the intellectual property regime, providing potential monopoly power to multinational agritech firms that would prohibit open access to the important public goods that should be created by the Bill.

I look forward to the Minister’s response and to working with noble Lords to deliver, I hope, a better Bill.

7.21 pm

Type
Proceeding contribution
Reference
825 cc1229-1233 
Session
2022-23
Chamber / Committee
House of Lords chamber
Back to top